Maravai LifeSciences Holdings, Inc. $MRVI Shares Bought by Parkman Healthcare Partners LLC

Key Points

• Parkman Healthcare Partners LLC increased its holdings in Maravai LifeSciences by 88.6% in Q1 2023, owning approximately 0.26% of the company, which is valued at about $1.46 million.
• Several hedge funds, including PenderFund Capital Management and Jacobs Levy Equity Management, also boosted their positions in Maravai, indicating a growing institutional interest.
• Equities research analysts have adjusted their price targets for Maravai LifeSciences, with a consensus target price of $5.22 and ratings ranging from Buy to Sell.

Parkman Healthcare Partners LLC grew its position in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report) by 88.6% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 660,000 shares of the company's stock after purchasing an additional 310,000 shares during the quarter. Parkman Healthcare Partners LLC owned approximately 0.26% of Maravai LifeSciences worth $1,459,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in the company. PenderFund Capital Management Ltd. grew its holdings in shares of Maravai LifeSciences by 42.4% during the first quarter. PenderFund Capital Management Ltd. now owns 826,300 shares of the company's stock worth $1,826,000 after purchasing an additional 246,000 shares during the last quarter. Philosophy Capital Management LLC purchased a new stake in Maravai LifeSciences in the 1st quarter valued at approximately $5,731,000. Jacobs Levy Equity Management Inc. boosted its holdings in Maravai LifeSciences by 437.0% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 493,582 shares of the company's stock valued at $1,091,000 after purchasing an additional 401,673 shares in the last quarter. 12 West Capital Management LP boosted its holdings in Maravai LifeSciences by 8.0% in the 1st quarter. 12 West Capital Management LP now owns 12,521,335 shares of the company's stock valued at $27,672,000 after purchasing an additional 930,000 shares in the last quarter. Finally, Immersion Corp purchased a new stake in Maravai LifeSciences in the 1st quarter valued at approximately $864,000. Hedge funds and other institutional investors own 50.25% of the company's stock.

Maravai LifeSciences Trading Up 6.4%

Shares of Maravai LifeSciences stock opened at $2.51 on Friday. The company has a debt-to-equity ratio of 0.68, a current ratio of 5.16 and a quick ratio of 4.49. Maravai LifeSciences Holdings, Inc. has a 1 year low of $1.66 and a 1 year high of $9.60. The company has a market capitalization of $640.95 million, a P/E ratio of -1.85 and a beta of 0.29. The business has a 50 day moving average price of $2.49 and a 200 day moving average price of $2.38.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Royal Bank Of Canada lowered their price objective on Maravai LifeSciences from $7.00 to $5.00 and set an "outperform" rating on the stock in a report on Tuesday, August 12th. Robert W. Baird reduced their price target on shares of Maravai LifeSciences from $3.00 to $2.00 and set a "neutral" rating for the company in a research report on Tuesday, May 13th. Finally, Craig Hallum reduced their price target on shares of Maravai LifeSciences from $12.00 to $10.00 and set a "buy" rating for the company in a research report on Tuesday, May 13th. Three research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $5.22.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.

Want to see what other hedge funds are holding MRVI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.